Efficacy of 177-Lutetium DOTATATE Peptide Receptor Radionuclide Therapy in patients with metastatic NENs and carcinoid syndrome refractory to somatostatin analogues

被引：0
|
作者：
Ratnayake, G. M. [1 ]
Koffas, A. [1 ]
Theocharopoulos, I [1 ]
Hayes, A. [1 ]
Navalkissoor, S. [1 ]
Gnanasegaran, G. [1 ]
Quigley, A. M. [1 ]
Khoo, B. [1 ]
Mandair, D. [1 ]
Grossman, A. [1 ]
Caplin, M. [1 ]
Alsadik, S. [1 ]
Clark, R. [1 ]
Toumpanakis, C. [1 ]
机构：
[1] Royal Free Hosp, ENETS Ctr Excellence, London, England
来源：
JOURNAL OF NEUROENDOCRINOLOGY | 2022年 / 34卷
关键词：
carcinoid syndrome; prrt;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
H24
引用
收藏
页码：157 / 157
页数：1
相关论文
共 50 条
  • [41] Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues
    Bodei, L.
    Pepe, G.
    Paganelli, G.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2010, 14 (04) : 347 - 351
  • [42] Dosimetry in Lu-177-DOTATATE peptide receptor radionuclide therapy: a systematic review
    Amit Nautiyal
    Sofia Michopoulou
    Matt Guy
    Clinical and Translational Imaging, 2024, 12 : 157 - 175
  • [43] Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE; dosimetric findings
    Mok, S.
    Tay, Y.
    Ng, D.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2014, 41 : S532 - S532
  • [44] 177Lu DOTATATE nanoparticles: A therapeutic option for peptide receptor radionuclide therapy
    Arora, Geetanjali
    Shukla, Jaya
    Ghosh, Sourabh
    Malhotra, Arun
    Bandohpadhyaya, Guru
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [45] Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Patients With Somatostatin Receptor-Expressing Neuroendocrine Tumors The First US Phase 2 Experience
    Delpassand, Ebrahim S.
    Samarghandi, Amin
    Zamanian, Sara
    Wolin, Edward M.
    Hamiditabar, Mohammadali
    Espenan, Gregory D.
    Erion, Jack L.
    O'Dorisio, Thomas M.
    Kvols, Larry K.
    Simon, Jaime
    Wolfangel, Robert
    Camp, Arthur
    Krenning, Eric P.
    Mojtahedi, Alireza
    PANCREAS, 2014, 43 (04) : 518 - 525
  • [46] Dramatic response with peptide receptor radionuclide therapy with 177Lu-DOTATATE and capecitabine in the treatment of metastatic thymic carcinoma
    Bal, C.
    Ballal, S.
    Tripati, M.
    Chakraborty, P.
    Thakral, P.
    Arora, G.
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56
  • [47] Treatment of Paragangliomas with Lutetium-177-Octreotate Based Peptide Receptor Radionuclide Therapy
    Duijzentkunst, Smit D.
    Kwekkeboom, D.
    NEUROENDOCRINOLOGY, 2017, 105 : 254 - 254
  • [48] Metastatic Mediastinal Carcinoid Presenting as Superior Mediastinal Syndrome and Treated With Peptide Receptor Radionuclide Therapy
    Malhotra, Gaurav
    Asopa, Ramesh V.
    CLINICAL NUCLEAR MEDICINE, 2014, 39 (01) : E89 - E92
  • [49] Peptide receptor radionuclide therapy (PRRT) of treatment-refractory metastatic thyroid cancer using Yttrium-90 and Lutetium-177 labeled somatostatin analogs: Toxicity, response and survival analysis
    Prasad, Vikas
    Budiawan, Hendra
    Salavati, Ali
    Hoersch, Dieter
    Zachert, C.
    Baum, Richard
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51
  • [50] Lutetium-177 Dotatate Therapy, Revolutionizing the Way Somatostatin Receptor-Positive Neuroendocrine Tumors are Treated
    Cesko, Aida
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
12345